|

5-fluorouracil Clinical Trials

40 actively recruiting trials across 21 locations

▲ +1 trial since August 2026

Also known as: 5-FU, 5FU, Adrucil, Carac, Efudex +5 more

Pipeline

Phase 1: 8Phase 2: 15Phase 3: 11Phase 1/2: 2Phase 2/3: 2

Top Sponsors

  • AstraZeneca5
  • Merck Sharp & Dohme LLC2
  • Memorial Sloan Kettering Cancer Center2
  • Janssen Research & Development, LLC2
  • Fujian Cancer Hospital2

Indications

  • Cancer40
  • Gastric Cancer7
  • Gastroesophageal Junction Adenocarcinoma4
  • Colorectal Cancer4
  • Oral Squamous Cell Carcinoma2

Other14 trials

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Phase 2
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Phase 2/3
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Phase 3
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
Phase 2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Phase 3
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Phase 2/3
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Phase 2
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Phase 2
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
N/A
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3

Phoenix, Arizona2 trials

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Mayo Clinic - Arizona ( Site 0090)

Phase 3
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Mayo Clinic Arizona

Phase 2

Tucson, Arizona2 trials

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The University of Arizona Cancer Center

Phase 1
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The University of Arizona Cancer Center-North Campus

Phase 3

Duarte, California2 trials

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1

Los Angeles, California2 trials

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Tampa, Florida2 trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Moffitt Cancer Center

Phase 2

Birmingham, Alabama1 trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Anchorage, Alaska1 trial

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3

Chandler, Arizona1 trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Ironwood Cancer and Research Center

Phase 3

Gilbert, Arizona1 trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3

Orange, California1 trial

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Research Site

Phase 2

Santa Monica, California1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

UCLA

Phase 2

Miami, Florida1 trial

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

University of Miami

Phase 1

Chicago, Illinois1 trial

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The University of Chicago

Phase 1

Bethesda, Maryland1 trial

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

National Institutes of Health Clinical Center

Phase 1

Boston, Massachusetts1 trial

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Massachusetts General Hospital (Data Collection Only)

Phase 2

St Louis, Missouri1 trial

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Washington University School of Medicine

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Phase 2

Lake Success, New York1 trial

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

START New York

Phase 1/2

New York, New York1 trial

Adaptive Radiation in Anal Cancer

Columbia University Irving Medical Center

N/A

Pittsburgh, Pennsylvania1 trial

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

St. Margaret Hospital Dermatology

Phase 1

Houston, Texas1 trial

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.